Ottobock, the global healthtech company and one of the international market leaders for customized prosthetic and orthotic mobility solutions, successfully continued its sustainable growth trajectory in 2024. According to preliminary figures, the company improved its 2024 revenue compared to the previous year by 7 percent to more than 1.6bn Euro (2023: 1.495bn Euro). Ottobock increased its operating result (adjusted EBITDA) in 2024 by 17 percent to over 325m Euro (2023: 280m Euro).

Oliver Jakobi, CEO of Ottobock SE & Co. KGaA: “Our 2024 track record shows yet again that our clear focus on innovation is paying off. We consistently translate technological leadership into commercial success, which drives sustainable growth, new standards and new markets. We are starting the new year with tailwinds, also on the basis of the newly established patient reimbursements in important markets and are confident that we will be able to continue our successful course in 2025.”

Ottobock reinforces market leadership

At last year's leading trade fair OTWorld in Leipzig, the new generation of the mechatronic Genium knee joint and the Evanto prosthetic foot were presented. Both the Genium X4 and the Evanto are considered important technical innovations in prosthetics. Ottobock was also successful in obtaining patient reimbursement for the Kenevo mechatronic knee joint in the USA. The C-Brace mechatronic orthosis system was already established in the US at the end of 2023 and will be available in France from 2025 via patient reimbursement. These factors contribute to our dynamic organic growth and demonstrate the success of our sustained high R&D investments with an R&D ratio of 6 percent.

Ottobock was also able to demonstrate its market leadership at the 2024 Paralympic Games. With more than 3,000 repairs, the technicians were in greater demand than ever in Paris last year. Ottobock has been providing technical service for more than 35 years. Its commitment to the Paralympics has already been pledged until 2032. Ottobock 2024 has received numerous awards for its sustainable Paralympic commitment, consistent implementation of the ESG sustainability strategy, marketing campaigns and as "Best Managed Company".

Consistent expansion of patient care network

Another success factor for the continued growth of the global market leader are the fitting centers, where Ottobock has direct access to its patients and offers customized orthopedic treatments. With more than
400 fitting centers, Ottobock already operates the largest international network.

Ottobock has successfully expanded this network through targeted investments, such as the acquisition of Sahva A/S, a leading provider of orthopaedic technology in Denmark, which significantly expanded Ottobock's presence in Scandinavia.

Operating profit margin increased to some 20.5 percent

Based on revenue growth and the consistent implementation of efficiency measures, Ottobock improved its operating EBITDA margin in 2024 to some 20.5 percent (2023: 19 percent). Further focusing of the business also contributed, and the sale of the US distributor Cascade had a direct positive impact on the margin.

Dr. Arne Kreitz, CFO of Ottobock SE & Co. KGaA: "As a medium-sized company, we focus our investments on those areas where we see the best opportunities for growth and earnings. We are expanding our technological innovation leadership in our focus areas and ensuring the future development of the company with high organic growth, increasing profit margins and healthy cash flow.